$0.39
2.42% today
Nasdaq, Apr 03, 06:32 pm CET
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Bolt Biotherapeutics Inc Stock price

$0.40
-0.04 9.21% 1M
-0.25 37.94% 6M
-0.13 25.06% YTD
-1.00 71.36% 1Y
-2.48 86.08% 3Y
-31.75 98.75% 5Y
-31.75 98.75% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 4.70%
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Key metrics

Market capitalization $15.37m
Enterprise Value $-7.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.12
EV/Sales (TTM) EV/Sales -0.98
P/S ratio (TTM) P/S ratio 2.00
P/B ratio (TTM) P/B ratio 0.27
Revenue growth (TTM) Revenue growth -2.36%
Revenue (TTM) Revenue $7.69m
EBIT (operating result TTM) EBIT $-68.24m
Free Cash Flow (TTM) Free Cash Flow $-61.33m
Cash position $48.11m
EPS (TTM) EPS $-1.65
P/E forward negative
P/S forward 4.07
EV/Sales forward negative
Short interest 0.08%
Show more

Is Bolt Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bolt Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Bolt Biotherapeutics Inc forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Bolt Biotherapeutics Inc forecast:

Hold
100%

Financial data from Bolt Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7.69 7.69
2% 2%
100%
- Direct Costs 1.78 1.78
47% 47%
23%
5.91 5.91
30% 30%
77%
- Selling and Administrative Expenses 17 17
13% 13%
217%
- Research and Development Expense 56 56
4% 4%
724%
-66 -66
9% 9%
-864%
- Depreciation and Amortization 1.78 1.78
47% 47%
23%
EBIT (Operating Income) EBIT -68 -68
10% 10%
-887%
Net Profit -63 -63
9% 9%
-821%

In millions USD.

Don't miss a Thing! We will send you all news about Bolt Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bolt Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
9 days ago
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeti...
Neutral
GlobeNewsWire
10 days ago
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care Conference Company presentation on Tuesday, March 4, 2025 at 3:10 p.m.
More Bolt Biotherapeutics Inc News

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Head office United States
CEO William Quinn
Employees 52
Founded 2015
Website www.boltbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today